chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The patient did not receive the second dose of RabAvert; Case reference number US-BN-2022-004969 is a spontaneous case initially received from other health professional via Communication (reference number: USBAV22-2199) on 28-Dec-2022 and concerns a female patient of an unknown age.  The patient's medical history and concomitant medication details were not provided.  On 29-Nov-2022, the patient was vaccinated with the first dose of RabAvert (rabies virus (inactivated, strain flury LEP) (PCEC); batch number: unknown) at an unknown dose, route or site of administration for rabies pre-exposure prophylaxis (rabies immunisation).  On an unspecified date, reported as 'on day 28', the patient thought was supposed to come for a second dose of RabAvert (batch number: unknown), however, the patient did not receive the second dose (explicitly coded as 'missed dose').  At the time of this report, it was unknown if the patient experienced any adverse event due to RabAvert.  Additional information received on 28-Dec-2022 included confirmation that the patient did not receive the second dose of RabAvert.  Additional information received on 29-Dec-2022 included local case ID.; Reporter's Comments: A female patient of unknown age was vaccinated with the first dose of RabAvert, at an unknown dose, route or site of administration for rabies pre exposure prophylaxis. 28 days after the first dose, the patient was supposed to come for a second dose of RabAvert, however, the patient did not receive the second dose which is considered as missed dose. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unknown age was vaccinated with the first dose of RabAvert, at an unknown dose, route or site of administration for rabies pre exposure prophylaxis. 28 days after the first dose, the patient was supposed to come for a second dose of RabAvert, however, the patient did not receive the second dose which is considered as missed dose. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Pt. states that she experienced pain in her right arm until a few days ago.  She states that the pain is gone now, but she has been experiencing tingling down her right arm into the top of her hand.
Dose Number: 1,2,3; COVID 19 Treatment; Dose Number: 1,2,3; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 40-year-old male patient received BNT162b2 (BNT162B2), on 01Apr2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 22Apr2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 16Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 40 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient did not have known allergies. Other medication in 2 weeks were None. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Dose Number: 1,2,3; COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Rebound of COVID symptoms and positive RAT 7 days after completion of Paxlovid course (14 days after first positive RAT). Positive RAT for next 6 days. Negative RAT on day 7 from rebound (day 21 from initial positive RAT); Negative, notes: Negative RAT on day 7 from rebound (day 21 from initial positive RAT); Unknown Results. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Paxlovid was given to the patient for covid-19 treatment on 01May2022 and stopped on 06May2022. Adverse event start date was provided as 14May2022. Rebound of COVID symptoms and positive RAT 7 days after completion of Paxlovid course (14 days after first positive RAT). Positive RAT for next 6 days. Negative RAT on day 7 from rebound (day 21 from initial positive RAT). Symptoms mostly resolved around day 5-6 after start of rebound; with lingering cough and intermittent fatigue remaining today (day 25 from first positive RAT; day 11 from rebound).  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
reported tingling in the arm that the vaccine was administered to, then becoming all over body itching. denied any hives developed urticaria and never saw a rash, but was itchy all over and looked red. took Claritin and Benadryl and felt better the next day.  has a history urticaria from sun exposure and temperature changes on skin .
After 1st dose on 3/1 and arm was sore and two day later Wednesday I started having issues, bad burning sensation inside and couldn't lay on it, I developed a rash on body and face. Everything that started happening happened on the same side as the vaccine I received. I am being treated for Shingles because all the symptoms are like Shingles, but it's on the inside
fever, headache, bp 155/79 (usdually in 110's 120's/ baseline), and nausea.  Caller wanted to know if any interaction with APAP.  Advised no interaction between Pfizer covid Vaccine and APAP, increase fluid intake as well, PIC will call back to f/u at later time.
fatigue,  weakness, mild GI discomfort, sleepiness, painful area 3" below injection site with erythema and slight swelling x3 days
Pts arm shows blotchy redness with flare, No wheals noticed "elevation." Pt stated the site was itchy/irritating as well.
pt symptoms presented as possible PE with SOB and elevated Ddimer.    MD sent her to the ER due to d dimer labs  no chf present no evidence of PE
Information has been received from a physician concerning a female patient of unknown age who on an unspecified date was vaccinated with an unknown dose of GARDASIL. The patient's medical history, past drug history and concomitant medications were unknown. On an unknown date the patient experienced seizures. It was unknown if any laboratory testing was performed. As of 21-APR-2010, the patient was no longer receiving GARDASIL and it was unknown if the seizures continued. It was unspecified if the patient sought medical attention. Upon internal review, seizures was considered serious as an other important medical event. Additional information has been requested.
Itchiness; Swollen down past elbow; Rash; Fever; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itchiness), PERIPHERAL SWELLING (Swollen down past elbow), RASH (Rash) and PYREXIA (Fever) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced PRURITUS (Itchiness), PERIPHERAL SWELLING (Swollen down past elbow), RASH (Rash) and PYREXIA (Fever). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL ALLERGY [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, PRURITUS (Itchiness), PERIPHERAL SWELLING (Swollen down past elbow), RASH (Rash) and PYREXIA (Fever) outcome was unknown.            Concomitant medications were not reported.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: Follow up received on 29-6-2021.No new event added. outcome updated
Anxiety, shortness of breath, gray out, LOC. Heart stopped and defib. 8/7/08-record received-Lower extremity venous duplex scan:enlarged lymph node in groin area no evidence of deep or superficial venous thrombosis.
Mother calls with concerns about her daughter who, after completing GARDASIL series, seemed to have flu like symptoms, achiness and then hip joint injury requiring P.T. that she was concerned due to some type of joint effect from vaccine.
Cellulitis on Right Arm, from shoulder to elbow. Treated with ATB.
This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (could not lift it for a day and a half), VACCINATION SITE PAIN (soreness in his arm after all three shots) and ARTHRALGIA (soreness in his shoulder) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011F21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included CLONIDINE for an unknown indication.    On 19-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MOBILITY DECREASED (could not lift it for a day and a half), VACCINATION SITE PAIN (soreness in his arm after all three shots) and ARTHRALGIA (soreness in his shoulder). At the time of the report, MOBILITY DECREASED (could not lift it for a day and a half), VACCINATION SITE PAIN (soreness in his arm after all three shots) and ARTHRALGIA (soreness in his shoulder) outcome was unknown.            No treatment medications were reported.  Patient reported that he is not immunocompromised but received a third full dose.   This case was linked to MOD-2021-359050, MOD-2021-359053 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 22-Oct-2021: Patient demographics were updated.
Flushing face, heavy tongue, light rash left arm, stomach irritation (nausea).Patient developed a reaction to COVID-19 vaccine 5 min. after injection administration flushing face, heavy tongue and light rash and nausea were the symptoms showed up by patient.   V/S  BP 198/886, P-63, Sat. 99%.   Patient transferred to  Hospital to get medical care and be under observation.
pain, couldn't lift my arm; my finges would turn colors; my hand and fingers were starting to go numb; it fluctuates between a burning sensation and my skin is being pulled; pain, couldn't lift my arm; tissue damage in that area; rash; pretty extensive swelling, just centrally located where the injection site was; went to bed with an itchy arm at night; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INJECTION SITE SWELLING (pretty extensive swelling, just centrally located where the injection site was), PAIN IN EXTREMITY (pain, couldn't lift my arm) and TISSUE INJURY (tissue damage in that area) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Jan-2021, the patient experienced INJECTION SITE SWELLING (pretty extensive swelling, just centrally located where the injection site was). On 13-Jan-2021, the patient experienced TISSUE INJURY (tissue damage in that area). On an unknown date, the patient experienced PAIN IN EXTREMITY (pain, couldn't lift my arm). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 1 dosage form. At the time of the report, INJECTION SITE SWELLING (pretty extensive swelling, just centrally located where the injection site was), PAIN IN EXTREMITY (pain, couldn't lift my arm) and TISSUE INJURY (tissue damage in that area) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient went to the emergency room on 05Jan2021 and reported using Benadryl topical cream on 05Jan2021 but stopped using it. On 11Jan2021, patient went to her primary care doctor. On13Jan2021 at urgent care, an x-ray showed that patient experienced tissue damage in that area. Concomitant medications were not reported.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2021: Follow up received on 08JUN-2021 contains of  new Adverse Event  added, reporter information added.
Spot was warm to the touch,Spot where she had the vaccine had some heat; Redness at the spot where she got the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Spot was warm to the touch,Spot where she had the vaccine had some heat) and VACCINATION SITE ERYTHEMA (Redness at the spot where she got the vaccine) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination.     No Medical history Information was reported.  Concomitant products included FLUCONAZOLE, TIZANIDINE, TRAMADOL, METOPROLOL, URSODIOL, OMEPRAZOLE (PROTONIX [OMEPRAZOLE]), ATORVASTATIN, HYDROXYCHLOROQUINE SULFATE (PLAQUENIL S), FAMOTIDINE (PEPCID AC), ACETYLSALICYLIC ACID (BABY ASPIRIN), CLOPIDOGREL BISULFATE (PLAVIX), FOLIC ACID, CALCIUM and VITAMIN D NOS for an unknown indication.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced VACCINATION SITE WARMTH (Spot was warm to the touch,Spot where she had the vaccine had some heat) and VACCINATION SITE ERYTHEMA (Redness at the spot where she got the vaccine). At the time of the report, VACCINATION SITE WARMTH (Spot was warm to the touch,Spot where she had the vaccine had some heat) and VACCINATION SITE ERYTHEMA (Redness at the spot where she got the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant Concomitant Medications were reported. No Treatment Information Provided.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
On 12/2/99, seen in urgent care with complaint of numb hands and feet from 12/1/99. Presented with numb hand and feet complaint along with a headache. Tongue and lip slightly numb, also, weak legs and noticed facial droop on left side. Admitted to the hospital. Dx in hospital with Guillain Barre Syndrome and treated with gammaglobulin. Symptoms worsened to point that pt could not even close his eyes. Spent 4 weeks in rehab after 2 weeks in hospital just to keep muscles going. He had a relapse 5 weeks ago when he became weaker. Follow up 06/05/2000: "Patients final diagnosis Gullian-Barre Syndrome.  Diagnosis was made by neurologist. Patient did not experience any other illness within the 4 weeks before the onset of GBS syndrome.  Patient received previously the influenza vaccine."
PATIENT WAS GIVEN INCORRECT VACCINE, NO ADVERSE REACTION WAS WITNESSED AT THE CLINIC AFTER PATIENT RECEIVED VACCINE.
About 10pm  my heart began beating very fast. Usual resting rate 62-72 bpm, it was between 90-110 bpm at rest, walking it went up once to 120. The elev rate lasted for several hours, then came into 80-90 range and stayed there for the next day. It still seems slightly elevated for me but is within normal range at this time.
Blurred vision, "heavy" feeling in the throat, nose became mostly numb, lips had some numbness, extreme paleness. No issues with breathing (even while wearing a mask).  Reaction started with blurred vision while reading (during the waiting period at the vaccination clinic). Started within 10 minutes of receiving vaccine.  Then the throat heaviness started, nose became numb, and lips were somewhat numb.  It occurred in waves, with a few minutes of symptoms, then a mild relief of symptoms (but not total relief), then symptoms returned. This continued for 30-45 minutes.   Received water and 2 Benadryl at the vaccination clinic from RN. Benadryl didn't seem to have any impact on symptoms.
Pt c/o "numbness/fullness under rt rib cage"; pt (employee) went to family MD; Onset of sx occured approx 2 days p/inject;
Headache; Arm soreness; Body aches; Sore throat; This is a spontaneous report from a contactable consumer. A 59-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the right arm on 06Apr2021 at 12:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not have any allergies to medications, food, or other products. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the right arm on 16Mar2021 at 12:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 05:00, the patient experienced headache, arm soreness, body aches and sore throat. Therapeutic measures were not taken as a result of the events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events headache, arm soreness, body aches and sore throat were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
After the first shot my arm hurt for ever after. After the second shot I had a high fever for 24 hrs. And joint pain that's been going on since the shot and has been on and off. I had symptoms of covid in early july and saw the doctor- cough, runny nose, and was sent to ER for chest xray.
One day post vax, the pt developed a red rash from head to toe, cried frequently; often for 3 hours straight. Did not sleep much, stared into space frequently for 3-4 weeks. Did not act himself for one month, during this time called pediatrician.
received first dose of Shingrix in 2019 but never received the 2nd dose; This non-serious case was reported by a physician via sales rep and described the occurrence of incomplete course of vaccination in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received first dose of Shingrix in 2019).   On an unknown date, the patient did not received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: received first dose of Shingrix in 2019 but never received the 2nd dose).  The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 03-OCT-2023 The reporter stated patient received his first dose of shingrix in 2019 but never received the second dose which led to incomplete course of vaccination. Th reporter wants to know what advice patient should be given and how long patient can wait to receive the second dose. The vaccine administration facility was the same as primary reporter for the 1st dose. The reporter consented to follow up.
RASH ON SIDE OF FACE AND NECK AND VERY ITCHY, OCCURRED WITHIN 7 DAYS OF THE VACCINE/PATIENT HAS NOT RECOVERED FROM THE ADR BUT  SAYS SHE IS IMPROVED NOW FROM WHEN IT STARTED
Patient received the Janssen vaccine on April 6 2021 and over the next week felt that her body was not right. She felt unsteady on her feet.  These symptoms continued and she was admitted to the hospital on 5/2/21. Her blood pressure was elevated at home and she was worried about a stroke. But had no focal weakness or headache. BP per report went to 220/110. CT scan was negative for stroke. MRI was unremarkable. She was given meclizine started on aspirin and atorvastatin and discharged. Since then she continues to have daily vertigo which prevents driving and she has been unable to work. She also has some nausea at times.
Light headedness, Nausea, Fever of 100.5 Fahrenheit, Redness/Pain at injection site, and Welts at injection site.
On 27 January 2006 the patient received YF, Hep A + Heb B, and Td in preparation for travel. Seven days after vaccination, she reported having a generalized rash; 4 days later she left for a foreign country where she was hospitalized with a fulminant illness reportedly characterized by fever (temp unknown), hypotension, and multiorgan failure. The specific clinical presentation and labortory data are not yet available from her physicians.
scratchy throat; body aches; flu-like symptoms; sick; scratchy throat/dry scratchy feeling that occasionally feels sore; Light headedness; muscle pain; chills; cough; Sore throat; This is a spontaneous report from a sponsored program.   A 38-years-old female patient received bnt162b2 (BNT162B2, PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: was not reported) via an unspecified route of administration, administered in Arm Left on 29Apr2021 (At the age of 38 years) as DOSE 2, SINGLE for covid-19 immunisation. The patient previously received bnt162b2 (BNT162B2, PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: was not reported), via an unspecified route of administration, administered in Arm Left on 08Apr2021 as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. Caller is a consumer who states she and her husband developed symptoms 9-10 days after they received their second dose of the Pfizer covid 19 vaccine. On an unspecified date, the patient had experienced scratchy throat, scratchy throat/dry scratchy feeling that occasionally feels sore, sick and bodyaches flu-like symptoms. On 08May2021, the patient had experienced muscle pain, chills, Sore throat and cough. On 09May2021, the patient had experienced light headedness. Her scratchy throat started Friday night or Saturday morning. It is that dry scratchy feeling that occasionally feels sore. They haven't been taking medicine. They have been taking a kind of Chloraseptic spray. It is just called Chloraseptic spray, it says sore throat relief. She does not have it on her right now. She took some Tylenol and stuff that is recommended. On 09May2021, the event chill was recovered. At the time of reporting, the event sore throat, cough, scratchy throat, Light headedness and muscle pain was not recovered and the outcome of the events body aches, flu-like symptoms, sick and scratchy throat/dry scratchy feeling that occasionally feels sore were unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.